4//SEC Filing
Francis Richard D 4
Accession 0000950170-24-016803
CIK 0000818686other
Filed
Feb 19, 7:00 PM ET
Accepted
Feb 20, 7:42 AM ET
Size
9.6 KB
Accession
0000950170-24-016803
Insider Transaction Report
Form 4
Francis Richard D
President and CEO
Transactions
- Exercise/Conversion
Ordinary Shares
2024-02-15+161,655→ 161,655 total - Sale
Ordinary Shares
2024-02-15$13.15/sh−74,530$980,174→ 87,125 total - Exercise/Conversion
Restricted Share Units
2024-02-15−161,655→ 323,311 total→ Ordinary Shares (161,655 underlying)
Footnotes (6)
- [F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- [F2]Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
- [F3]The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 13, 2023.
- [F4]Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.09 to $13.24, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F6]Restricted share units were granted on February 15, 2023, with 161,655 vesting on each of February 15, 2024 and February 15, 2025, and 161,656 vesting on February 15, 2026.
Documents
Issuer
TEVA PHARMACEUTICAL INDUSTRIES LTD
CIK 0000818686
Entity typeother
Related Parties
1- filerCIK 0001673277
Filing Metadata
- Form type
- 4
- Filed
- Feb 19, 7:00 PM ET
- Accepted
- Feb 20, 7:42 AM ET
- Size
- 9.6 KB